Pre-Admission Statin Use and In-Hospital Severity of 2009 Pandemic Influenza A(H1N1) Disease
Open Access
- 25 April 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (4) , e18120
Abstract
Statins are drugs that are used to lower plasma cholesterol levels. Recently, contradictory claims have been made about possible additional effects of statins on progression of a variety of inflammatory disorders, including infections. We therefore examined the clinical course of patients admitted to hospital with 2009 pandemic influenza A(H1N1), who were or weren't taking statins at time of admission. A retrospective case-control study was performed using the United Kingdom Influenza Clinical Information Network (FLU-CIN) database, containing detailed information on 1,520 patients admitted to participating hospitals with confirmed 2009 pandemic influenza A(H1N1) infection between April 2009 and January 2010. We confined our analysis to those aged over 34 years. Univariate analysis was used to calculate unadjusted odds ratios (OR) and 95 percent confidence intervals (95%CI) for factors affecting progression to severe outcome (high dependency or intensive care unit level support) or death (cases); two multivariable logistic regression models were then established for age and sex, and for age, sex, obesity and “indication for statin” (e.g., heart disease or hypercholesterolaemia). We found no statistically significant association between pre-admission statin use and severity of outcome after adjustment for age and sex [adjusted OR: 0.81 (95% CI: 0.46–1.38); n = 571]. After adjustment for age, sex, obesity and indication for statin, the association between pre-admission statin use and severe outcome was not statistically significant; point estimates are compatible with a small but clinically significant protective effect of statin use [adjusted OR: 0.72 (95% CI: 0.38–1.33)]. In this group of patients hospitalized with pandemic influenza, a significant beneficial effect of pre-admission statin use on the in-hospital course of illness was not identified. Although the database from which these observations are derived represents the largest available suitable UK hospital cohort, a larger study would be needed to confirm whether there is any benefit in this setting.Keywords
This publication has 27 references indexed in Scilit:
- Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adultsThorax, 2011
- Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009)Thorax, 2010
- Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenzaCanadian Medical Association Journal, 2010
- Critical Care Services and 2009 H1N1 Influenza in Australia and New ZealandNew England Journal of Medicine, 2009
- Critically Ill Patients With 2009 Influenza A(H1N1) Infection in CanadaJAMA, 2009
- Risk of community‐acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population‐based case–control studyPharmacoepidemiology and Drug Safety, 2009
- Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza PreparednessThe Journal of Infectious Diseases, 2008
- Statins and sepsis: multiple modifications at multiple levelsThe Lancet Infectious Diseases, 2007
- The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases*Critical Care Medicine, 2007
- Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort studyBMJ, 2006